Down-regulation of cell surface CXCR6 expression during T cell activation is predominantly mediated by calcineurin.
CXCR6, the receptor for the membrane-anchored chemokine, CXCL16, is expressed on a subset of CCR5-bearing memory T cells, and may play a role in recruiting these cells to sites of inflammation. Here, we set out to determine the effect of T cell activation on CXCR6 expression. Highly purified human peripheral blood T cells were cultured for 7-8 days in presence of IL-2 (400 U/ml) to enhance CXCR6 expression. Overnight stimulation with anti-CD3 mAb+anti-CD28 mAb, which resulted in CD69 induction and cytokine (IL-2 and IFN-gamma) production, reduced cell surface expression of CXCR6 by 85% and that of CCR5 by 76%. The Ca(2+) ionophore, ionomycin (125-500 ng/ml), also markedly diminished CXCR6 expression (85%), but without inducing CD69 expression or cytokine production, and reduced CCR5 expression by only 40%. In contrast, the phorbol esters, PdBu or PMA had little effect on CXCR6 expression (23% reduction) but induced CD69 expression and caused a profound down-regulation (92%) of CCR5 expression. Moreover, CCR7, whose expression was low on CXCR6(+) T cells, was little affected by any of these modes of activation. The down-regulation of CXCR6 expression induced by CD3/CD28 activation was blocked by the broad kinase inhibitor, staurosporine, and by the src kinase inhibitor, PP2, but not by the MEK1 inhibitor, U0106. Most interestingly, the calcineurin inhibitor, FK506, consistently inhibited CD3/CD28-induced CXCR6 down-regulation. FK506 also blocked the decrease of CXCR6 expression caused by ionomycin, whereas staurosporine or PP2 had no effect on this decrease. Altogether, these data indicate that CXCR6 expression is down-regulated, independent of CCR5 or CD69 expression and of cytokine induction, by T cell activation signals that involve predominantly the Ca(2+)-dependent calcineurin pathway.
Koprak
Samuel
S
Department of Immunology and Rheumatology, 126 East Lincoln Avenue, Room RY80W107, Rahway, NJ 07065, USA. sam_koprak@merck.com
Matheravidathu
Stephen
S
Springer
Martin
M
Gould
Sandra
S
Dumont
Francis J
FJ
D015703:Antigens, CD / Q000276:immunology; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology; D002070:Butadienes / Q000494:pharmacology; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism / Q000502:physiology; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism / Q000502:physiology; D019703:Calcineurin / Q000276:immunology*; D016207:Cytokines / Q000276:immunology; D015536:Down-Regulation / Q000187:drug effects / Q000276:immunology; D005434:Flow Cytometry; D006801:Humans; D007166:Immunosuppressive Agents; D007376:Interleukin-2 / Q000276:immunology; D037181:Lectins, C-Type; D008213:Lymphocyte Activation / Q000276:immunology*; D009570:Nitriles / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D054400:Receptors, CCR7; D000075744:Receptors, CXCR6; D019707:Receptors, Chemokine / Q000276:immunology / Q000378:metabolism; D018121:Receptors, Cytokine / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D043562:Receptors, G-Protein-Coupled; D011991:Receptors, Virus; D015398:Signal Transduction / Q000276:immunology; D019311:Staurosporine / Q000494:pharmacology; D016559:Tacrolimus / Q000494:pharmacology; D000099192:CD69 Antigens
D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D002070:Butadienes; D019703:Calcineurin; D016207:Cytokines; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D037181:Lectins, C-Type; D009570:Nitriles; D011743:Pyrimidines; D054400:Receptors, CCR7; D000075744:Receptors, CXCR6; D019707:Receptors, Chemokine; D018121:Receptors, Cytokine; D043562:Receptors, G-Protein-Coupled; D011991:Receptors, Virus; D019311:Staurosporine; D016559:Tacrolimus; D000099192:CD69 Antigens; C412373:AG 1879; C515370:CCR7 protein, human; C106330:CXCR6 protein, human; C113580:U 0126